PANBELA THERAPEUTICS INC (PBLA)
PBLA moved a median of 0.00% 30 minutes after news, and -0.77% by the close. How PBLA actually reacts to news — the realized, point-in-time move the market made, measured across 148 labeled events over the last three years with zero look-ahead.
PBLA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 14% | 145 |
| 30-min | 0.00% | 15% | 147 |
| 60-min | -1.64% | 14% | 147 |
| to close | -0.77% | 33% | 147 |
| Middle 50% of PBLA reactions | -5.74% to 0.00% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 148 |
Half of all PANBELA THERAPEUTICS INC news events land between -5.74% and +0.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when PBLA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PBLA's baseline. Nothing else.
Recent PBLA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form SEC STAFF ACTION Panbela Therapeutics, | SEC filing · Form SEC | SEC EDGAR | — | — | |
| Form 8-K Panbela Therapeutics, For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.09% | |
| Form 8-K Panbela Therapeutics, For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K Panbela Therapeutics, For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.19% | |
| Form S-8 Panbela Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +1.39% | |
| Form 8-K Panbela Therapeutics, For: Nov 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.03% | |
| Form 10-Q Panbela Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +8.42% | |
| Form 8-K Panbela Therapeutics, For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +8.42% | |
| Panbela Provides Business Update and Reports Q3 2024 Financial Results | Press release | GlobeNewswire | +0.00% | +8.42% | |
| Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024 | Press release | GlobeNewswire | +0.00% | -0.68% | |
| Form 8-K Panbela Therapeutics, For: Oct 22 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K Panbela Therapeutics, For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.85% | |
| First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center | Press release | GlobeNewswire | +1.41% | -4.22% | |
| Form S-1/A Panbela Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | +0.00% | +19.62% | |
| Form 10-Q Panbela Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K Panbela Therapeutics, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Panbela Provides Business Update and Reports Q2 2024 Financial Results | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 8-K Panbela Therapeutics, For: Jul 24 | SEC filing · Form 8-K | SEC EDGAR | -8.99% | -9.02% | |
| Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024 | Press release | GlobeNewswire | -8.99% | -9.02% | |
| Form 8-K Panbela Therapeutics, For: Jun 28 | SEC filing · Form 8-K | SEC EDGAR | +13.49% | +4.23% | |
| Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification | Press release | GlobeNewswire | +0.00% | -3.75% | |
| Panbela Announces Oral Presentation at Digestive Disease Week (DDW): | Press release | GlobeNewswire | +0.00% | -4.65% | |
| Form 8-K Panbela Therapeutics, For: May 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -9.49% | |
| Form 10-Q Panbela Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -18.37% | -2.04% | |
| Form 8-K Panbela Therapeutics, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -18.37% | -2.04% | |
| Panbela Provides Business Update and Reports Q1 2024 Financial Results | Press release | GlobeNewswire | -18.37% | -2.04% | |
| Form DEFR14A Panbela Therapeutics, | SEC filing · Form DEFR14A | SEC EDGAR | +0.00% | -2.31% | |
| Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac | Press release | GlobeNewswire | +0.00% | +2.20% | |
| Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024 | Press release | GlobeNewswire | +0.00% | -20.53% | |
| Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week | Press release | GlobeNewswire | +2.21% | -0.12% | |
| Form PRER14A Panbela Therapeutics, | SEC filing · Form PRER14A | SEC EDGAR | +0.00% | +8.81% | |
| Form 8-K Panbela Therapeutics, For: Apr 23 | SEC filing · Form 8-K | SEC EDGAR | +22.86% | +17.14% | |
| Form DEFA14A Panbela Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +22.86% | +17.14% | |
| Form 8-K Panbela Therapeutics, For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +18.70% | |
| Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025 | Press release | GlobeNewswire | +0.00% | +18.70% | |
| Form S-1 Panbela Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | -0.02% | -8.46% | |
| Panbela Announces Poster Presentation at American Association for Cancer Research: | Press release | GlobeNewswire | +0.00% | -2.10% | |
| Form 8-K Panbela Therapeutics, For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.45% | |
| Form EFFECT Panbela Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -1.45% | |
| Panbela Announces Transfer to OTCQB Market | Press release | GlobeNewswire | +0.00% | -1.45% | |
| Form DEF 14A Panbela Therapeutics, For: May 03 | SEC filing · Form DEF | SEC EDGAR | -0.02% | -0.81% | |
| Form EFFECT Panbela Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -3.18% | +4.38% | |
| Form POS AM Panbela Therapeutics, | SEC filing · Form POS | SEC EDGAR | +0.00% | -15.38% | |
| Form S-1 Panbela Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | +0.00% | -15.38% | |
| Form 10-K Panbela Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -5.15% | -0.77% | |
| Form 8-K Panbela Therapeutics, For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -5.15% | -0.77% | |
| Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results | Press release | GlobeNewswire | -5.15% | -0.77% | |
| Form PRE 14A Panbela Therapeutics, For: Mar 25 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +3.23% | |
| Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024 | Press release | GlobeNewswire | +6.83% | +2.12% | |
| Form 8-K Panbela Therapeutics, For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | +37.12% | +4.53% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PBLA section they belong to.
Where else PBLA is measured.
PBLA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is PANBELA THERAPEUTICS INC's median reaction calculated?
Every labeled PBLA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 148 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 15% of PBLA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PBLA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.